Scientists hunt for relapse clues in TTP Patients' immune cells
NCT ID NCT06945861
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at blood samples from 44 people with thrombotic thrombocytopenic purpura (TTP) to understand how certain immune cells (B and T lymphocytes) react to the ADAMTS13 protein during different stages of the disease. The goal is to find early warning signs that could predict a relapse, so doctors can personalize treatment to keep patients in remission longer. Participants must be over 18 and treated at Rouen University Hospital.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Rouen Hospital,
RECRUITINGRouen, 76031, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New enzyme replacement therapy aims to stop dangerous blood clots in rare disease
- New hope for rare blood disorder: study reviews real-world use of enzyme therapy
- New enzyme therapy shows promise in controlling rare blood clotting disorder
- New study tracks safety of adzynma for rare blood clot disorder
- New drug ADZYNMA tracked for safety in rare blood disorder
- New drug could reduce need for plasma exchange in rare blood disorder